Albert Schweitzer Ziekenhuis

Futó vizsgálatok

• Toboroz

  Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)

  2025-525068-13-00· 2. fázis· Forrás

• Még nem toboroz

  Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With Pirtobrutinib in Combination With Epcoritamab if the Disease Comes Back After Previous Treatment.

  NCT07860775· 2. fázis· Forrás

• Toboroz

  HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of venetoclax upon recurrence of the disease after previous treatment

  2025-524283-38-00· 3. fázis· Forrás

• Még nem toboroz

  HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before

  2025-524230-25-00· 2. fázis· Forrás

• Még nem toboroz

  Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

  NCT07486687· 3. fázis· Forrás

• Toboroz

  Clinical Impact of Using IMPROVE to Select Patients for Carotid Revascularisation

  NCT07556887· Forrás

• Toboroz

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· 3. fázis· Forrás

• Toboroz

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· 3. fázis· Forrás

• Toboroz

  A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  NCT07277231· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

  NCT07219602· 3. fázis· Forrás

• Toboroz

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· 3. fázis· Forrás

• Toboroz

  OPtimal stEnt Deployment stRategy oF Contemporary sTents - Registry to Evaluate Percutaneous Coronary Intervention Using Bioresorbable Scaffolds With Thinner-strut Construction and Guidance by intracOronary Imaging to REduce Scaffold Failure

  NCT06919562· Forrás

• Toboroz

  ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

  NCT07188025· 3. fázis· Forrás

• Fut, nem toboroz

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)

  2024-516652-18-00· 3. fázis· Forrás

• Toboroz

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

  2024-516654-22-00· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· 3. fázis· Forrás

• Toboroz

  A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.

  2024-512753-24-00· 3. fázis· Forrás

• Még nem toboroz

  A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC

  2025-520792-67-00· 3. fázis· Forrás

• Fut, nem toboroz

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· 3. fázis· Forrás

• Fut, nem toboroz

  An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  NCT06991556· 2. fázis· Forrás

• Toboroz

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· 3. fázis· Forrás

• Toboroz

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· 3. fázis· Forrás

• Toboroz

  ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

  NCT06902558· 2. fázis· Forrás

• Toboroz

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· 3. fázis· Forrás

• Toboroz

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· 4. fázis· Forrás

• Toboroz

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· 3. fázis· Forrás

• Toboroz

  Bascom Cleft Lift for Primary Wound Healing in Complex and Recurrent Sacrococcygeal Pilonidal Sinus Disease

  NCT06683274· Forrás

• Toboroz

  Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)

  2022-502352-31-00· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  NCT06717347· 3. fázis· Forrás

• Toboroz

  Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance

  2023-507489-20-00· 4. fázis· Forrás

• Toboroz

  Stopping or continuing blood thinners after stroke at young age without a known cause: STOP trial

  2024-513092-40-00· 4. fázis· Forrás

• Toboroz

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· 3. fázis· Forrás

• Toboroz

  DAROTAXEL

  2024-516939-28-00· 2. fázis· Forrás

• Toboroz

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· 3. fázis· Forrás

• Fut, nem toboroz

  First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial)

  NCT04639362· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  2024-510965-41-00· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

  NCT06500884· 2. fázis· Forrás

• Toboroz

  Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

  NCT06220032· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT06508658· 3. fázis· Forrás

• Toboroz

  Spinal Cord Monitoring in Multiple Sclerosis

  NCT06827834· Forrás

• Toboroz

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· 3. fázis· Forrás

• Fut, nem toboroz

  PreVent-ACaLL

  NCT03868722· 2. fázis· Forrás

• Toboroz

  FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)

  NCT06187441· 3. fázis· Forrás

• Fut, nem toboroz

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· 3. fázis· Forrás

• Toboroz

  Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

  NCT05791409· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· 3. fázis· Forrás

• Toboroz

  Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

  NCT06093672· 3. fázis· Forrás

• Toboroz

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

  NCT06079879· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Krónikus limfoid leukémia (CLL)7 toboroz
• Mielóma multiplex5 toboroz
• Akut mieloid leukémia (AML)4 toboroz
• Stroke (szélütés)4 toboroz
• Vastagbélrák4 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)3 toboroz
• Koszorúér-betegség3 toboroz
• Krónikus vesebetegség3 toboroz
• Prosztatarák3 toboroz
• Szívelégtelenség3 toboroz
• Elhízás2 toboroz
• Sclerosis multiplex (SM)2 toboroz
• Tüdőrák2 toboroz
• Zsírmáj (MASLD/MASH)2 toboroz
• Familiáris hiperkoleszterinémia1 toboroz
• Magas vérnyomás1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Tripla negatív emlőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· 2. fázis· Forrás

• Lezárult

  A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study

  2024-516511-24-00· 4. fázis· Forrás

• Lezárult

  Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point of view. Tailoring of treatment is done by taking the presence of autoantibodies and the quick response to glucocorticoids and JAK inhibitors into account.

  2024-511530-12-01· 4. fázis· Forrás

• Lezárult

  Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

  NCT06153693· 3. fázis· Forrás

• Lezárult

  Effect of Music Prehabilitation on Preoperative Anxiety Before Surgery

  NCT05982184· Forrás

• Fut, nem toboroz

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· 3. fázis· Forrás

• Lezárult

  The effect of oral folinic acid to prevent pemetrexed induced adverse events.

  2022-502345-10-00· 4. fázis· Forrás

• Lezárult

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· 3. fázis· Forrás

• Fut, nem toboroz

  A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

  NCT05567796· 3. fázis· Forrás

• Lezárult

  A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

  NCT05254002· 2. fázis· Forrás

• Lezárult

  A clinical study to investigate if the investigational drug Diamyd is safe and can preserve insulin production and secretion in adolescents and adults that have recently been diagnosed type 1 diabetes. The safety of Diamyd will also be investigated. Some subjects may receive a placebo drug.

  NCT05018585· 3. fázis· Forrás

• Lezárult

  Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

  NCT05142722· 3. fázis· Forrás

• Lezárult

  Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy

  NCT04753749· Forrás

• Lezárult

  Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

  NCT04472598· 3. fázis· Forrás

• Lezárult

  A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

  NCT04458831· Forrás

• Lezárult

  Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

  NCT04008706· 3. fázis· Forrás

• Lezárult

  Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  NCT03872401· 3. fázis· Forrás

• Lezárult

  A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

  NCT03652064· 3. fázis· Forrás

• Lezárult

  A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

  NCT03734016· 3. fázis· Forrás

• Lezárult

  Confirm Rx Insertable Cardiac Monitor SMART Registry

  NCT03505801· Forrás

• Lezárult

  Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide

  NCT03184194· 2. fázis· Forrás

• Lezárult

  Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

  NCT03048825· 3. fázis· Forrás

• Lezárult

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· 3. fázis· Forrás

• Lezárult

  A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL) with or without TP53 aberrations, HOVON 141 CLL / VIsion Trial of the HOVON and Nordic CLL study groups

  NCT03226301· 2. fázis· Forrás

• Lezárult

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· 3. fázis· Forrás

• Lezárult

  GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL)

  2024-511048-22-00· 2. fázis· Forrás

• Lezárult

  Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing a drug called Nilotinib versus another called Imatinib with switch to Nilotinib in absence of optimal response.

  NCT02602314· 4. fázis· Forrás

• Lezárult

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· 3. fázis· Forrás

• Fut, nem toboroz

  An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT02257736· 3. fázis· Forrás

• Lezárult

  Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

  NCT02162563· 3. fázis· Forrás

• Lezárult

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· 3. fázis· Forrás

Vizsgálati helyszínek

• Albert Schweitzer Ziekenhuis112 vizsgálat
• Albert Schweitzer Ziekenhuis, Dordrecht1 vizsgálat
• Albert Schweitzer Ziekenhuis - Dordwijk0 vizsgálat
• Albert Schweitzer Ziekenhuis / Hartcentum Dordrecht- Gorinchem1 vizsgálat
• Albert Schweitzer Ziekenhuis /ID# 2240151 vizsgálat
• Albert Schweitzer Ziekenhuis /ID# 2295600 vizsgálat
• Albert Schweitzer Ziekenhuis /ID# 2477400 vizsgálat
• Albert Schweitzer Ziekenhuis - Investigational Site Number : 58200011 vizsgálat
• Albert Schweitzer Ziekenhuis, Locatie Dordwijk5 vizsgálat
• Albert Schweitzer Ziekenhuis, locatie Dordwijk /ID# 2633611 vizsgálat
• Albert Schweitzer Ziekenhuis, locatie Dordwijk /ID# 2749360 vizsgálat
• Albert Schweitzer Ziekenhuis, locatie Dordwijk-Internal Medicine (Site 2302)0 vizsgálat
• Albert Schweitzer Ziekenhuis, locatie Dordwijk (Site 1901)1 vizsgálat
• Albert Schweitzer Ziekenhuis (Site 2103)0 vizsgálat
• Albert Schweitzer Ziekenhuis - Sliedrecht1 vizsgálat
• Albert Schweitzer Ziekenhuis1 vizsgálat
• Albert Schweitzer Ziekenhuis4 vizsgálat
• Albert Schweitzer Ziekenhuis - Location Dordrecht1 vizsgálat

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Krónikus limfoid leukémia (CLL)8 munka · 17 vizsgálat